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ABSTRACT
Objective: The risk of premature mortality is increased in people with epilepsy. The reasons for
this and how it may relate to epilepsy etiology remain unclear.
Methods: The National General Practice Study of Epilepsy is a prospective, community-based
cohort that includes 558 people with recurrent unprovoked seizures of whom 34% died during
almost 25 years of follow-up. We assessed the underlying and immediate causes of death and
their relationship to epilepsy etiology. Psychiatric and somatic comorbidities of epilepsy as pre-
dictors of mortality were scrutinized using adjusted Cox proportional hazards models.
Results: The 3 most common underlying causes of death were noncerebral neoplasm, cardiovas-
cular, and cerebrovascular disease, accounting for 59% (111/189) of deaths, while epilepsy-
related causes (e.g., sudden unexplained death in epilepsy) accounted for 3% (6/189) of deaths.
In 23% (43/189) of individuals, the underlying cause of death was directly related to the epilepsy
etiology; this was significantly more likely if death occurred within 2 years of the index seizure
(percent ratio 4.28 [95% confidence interval 2.63–6.97]). Specific comorbidities independently
associated with increased risk of mortality were neoplasms (primary cerebral and noncerebral
neoplasm), certain neurologic diseases, and substance abuse.
Conclusions: Comorbid diseases are important causes of death, as well as predictors of prema-
ture mortality in epilepsy. There is an especially strong relationship between cause of death
and epilepsy etiology in the first 2 years after the index seizure. Addressing these issues may help
stem the tide of premature mortality in epilepsy. Neurology® 2016;86:704–712
GLOSSARY
CI 5 confidence interval; COD 5 causes of death; GP 5 general practitioner; HR 5 hazard ratio; ICD 5 International Clas-
sification of Diseases; NGPSE 5 National General Practice Study of Epilepsy; NHS 5 National Health Service; PMR 5
proportionate mortality rate; SMR 5 standardized mortality ratio; SUDEP 5 sudden unexplained death in epilepsy.
Recent work has highlighted that people with epilepsy have premature mortality relative to the
general population. This has been consistently shown in high-income countries such as the
United Kingdom,1 United States,2 Sweden,3 and Iceland,4 as well as low- to middle-income
countries such as Bolivia,5 India,6 and China.7 The reasons for this are not apparent and warrant
further investigation.
Prior studies have described the distribution of causes of death (COD) in those with epilepsy
but few have distinguished between underlying and immediate causes.7–13 There is a paucity of
data examining the relationship between epilepsy etiology and COD.14,15 There have been
attempts to describe predictors of premature mortality, including nonadherence to antiepileptic
drugs, psychiatric disorders, cognitive impairment, and age,11,16,17 but there have been no com-
prehensive assessments of the role of the full spectrum of somatic and psychiatric comorbidities
in predicting mortality in an epilepsy cohort.
We describe the underlying and immediate CODs seen in a large community-based prospec-
tive cohort of people with epilepsy with almost 25 years of follow-up and inquire into the
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relationship between underlying COD and
epilepsy etiology as well as examine for predic-
tors of mortality, with a particular emphasis on
somatic and psychiatric comorbidities.
METHODS The National General Practice Study of Epilepsy
(NGPSE) is a longitudinal cohort study of people with incident
epileptic seizures, the methods of which have been described pre-
viously.1,18 Participants were initially identified between June
1984 and October 1987 by 275 participating general practi-
tioners (GPs) from across the United Kingdom who were asked
to report any person of any age with newly suspected epileptic
seizures. A diagnostic panel reviewed all potential participants and
identified those with definite or probable epileptic seizures. Of the
initial 1,195 people registered, 792 (66.3%) had had epileptic
seizures. The remaining individuals were diagnosed with febrile
seizures (n5 220), previously diagnosed epilepsy or neonatal seiz-
ures (n 5 104), or no clear history of epileptic seizures (n 5 79).
For the purposes of this report, we excluded those with a sin-
gle recorded seizure and those with acute symptomatic seizures
(i.e., occurring within 90 days of a precipitating cerebral injury).
This resulted in 558 individuals with recurrent unprovoked epi-
leptic seizures, i.e., epilepsy.19
The initial round of data collection carried out between 1984
and 1987 elicited data on basic demographics and clinical charac-
teristics. Additional information was sought on all possible
somatic and psychiatric comorbidities. This final set of queries
used pointed (i.e., requiring an affirmative or negative response)
and open-ended questions (i.e., requiring a free-text response), in-
structing GPs to record any additional conditions the individual
may have. There were a total of 12 rounds of data collection on
participant comorbidities, up until 2001. Following this, after the
passage of the UK Data Protection Act of 199820 and the Health
and Social Care Act of 2001,21 the collection of comorbidity
data was expressly not allowed during the 2009 follow-up. A
single study author (M.R.K.) reviewed the reported comorbidities
and coded the associated ICD-10 chapter22 and the date
when it was first reported. The 10th version of the ICD is a
system developed and supported by the WHO that classifies
human disease into 20 different categories. Comorbidities that
were only listed on the death certificates were not included in this
analysis as this would have created a bias differential to those who
have died.
All individuals in the NGPSE have been flagged at the UK
National Health Service (NHS) Information Centre and the inves-
tigators are sent a copy of the death certificate whenever a person
dies. This ensures complete mortality ascertainment, assuming that
the participant dies within the territorial boundaries of the United
Kingdom or that the NHS was notified of the death if the partic-
ipant died elsewhere. Each death certificate respects the WHO’s
recommended format and includes fields for recording up to 3
CODs as well as field II (i.e., “Other significant conditions con-
tributing to the death”).23We included all deaths occurring up until
October 5, 2009, in this report.
Only selected data related to the distribution of CODs from
the NGPSE have been reported.1,24,25 Previously we identified
one primary COD based upon the clinical judgment of the in-
vestigators, frequently using the first condition described on the
death certificate. Now we present complete COD data and
strictly distinguish between underlying COD and immediate
COD. The distinction between these 2 types of COD reflects
which condition initiated a series of events leading to death (i.e.,
the underlying COD) vs the condition that occurred only just
prior to death (i.e., immediate COD). The Sixth Decennial Inter-
national Revision Conference of the WHO resolved that the
underlying COD be reported as the main COD in all official
reporting.23,26 Care was taken to record the underlying COD
according to the General Principle and selection rules as laid
out in the ICD-10 manual.23 As such, pneumonia and pulmonary
embolism were considered immediate CODs unless there were
no other CODs listed on the death certificate, in which case they
were recorded as “pneumonia or pulmonary embolism not oth-
erwise specified.” Cardiac or respiratory failure is a mode of death
and not a COD23; if no other condition was listed on the death
certificate, the underlying and immediate CODs were coded as
“Other.” Vascular dementia was coded as dementia rather than
cerebrovascular disease. Each COD was described as a propor-
tionate mortality rate (PMR), where the numerator was the num-
ber of deaths due to a particular COD and the denominator the
total number of deaths within the NGPSE.27
The underlying epilepsy etiology was characterized for all in-
dividuals. This was done using data provided by GPs up until the
timing of the diagnostic panel. One study author (M.R.K.),
unaware of any other characteristic of each person, including
the timing of death, determined whether the underlying COD
was directly related to the epilepsy etiology for that individual
(e.g., due to a primary cerebral neoplasm or to cerebrovascular
disease). Death from an external cause was generally not consid-
ered related to post-traumatic epilepsy unless these were the same
event.
Statistical analyses. Differences in proportions were tested
using 2-sided Fisher exact test. A Holms-Bonferroni correction
was used to control for the effect of multiple comparisons.28
Cox proportional hazards regression was used to model asso-
ciations between each ICD comorbidity chapter and all-cause
mortality. Each ICD chapter was first regressed using a simple
model where age (categorized into approximate quartiles) at the
time of the index seizure (the event that led to presenting to med-
ical attention) and sex were included as covariates. ICD chapters
found to have a p , 0.10 in the simple model were included in
the fully adjusted model, along with age at the time of the index
seizure, participant sex, and early epilepsy remission (defined as
an absence of seizures more than 1 year after the index event).
The period at risk for each participant began with the time of the
index seizure and ended with the time of death or, if alive,
October 5, 2009. With the exception of ICD chapters 16 and
17, which are by definition congenital, each ICD chapter was
treated as a categorically time-varying covariate with the exposure
beginning when it was first reported to the NGPSE investigators.
Schoenfeld residuals were used to confirm the proportionality
assumption in the fully adjusted regression models.29
We used additional regression models to investigate the indi-
vidual comorbid conditions contained within those ICD chapters
that were significant predictors of all-cause mortality (in the fully
adjusted ICD chapter models) as well as those that were of partic-
ular clinical interest (e.g., all neurologic and psychiatric diseases).
Simple and fully adjusted regression models were carried out in a
similar manner to that for the ICD chapters.
STATA/SE, version 12.0 (StataCorp LP, College Station,
TX) was used to conduct all statistical analyses.
Standard protocol approvals, registrations, and patient
consents. The NGPSE was approved by the National Research
Ethics Committee (reference 07/H0720/160) and the National
Information Governance Board Ethics and Confidentiality Com-
mittee (PIAF 1–05[g]/2008 NGPSE). The requirement for indi-
vidual participant consent was waived.
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RESULTS The clinical characteristics and demo-
graphics of the cohort are presented in table 1. There
were 190 deaths during the follow-up period
although the death certificate for one person was
not available (who was therefore excluded from the
COD-related analyses).
The distribution of underlying CODs is depicted
in figure 1A. A majority of deaths were due to non-
cerebral neoplasm, cardiovascular disease, or cerebro-
vascular disease (58.7% or 111/189), while external
causes (4.2% or 8/189) and epilepsy-related causes
(e.g., sudden unexplained death in epilepsy [SUDEP]
or status epilepticus) (3.2% or 6/189) accounted for
a minority. Twenty-nine percent (12/41) of the fatal
noncerebral neoplasms were responsible for an indi-
vidual’s epilepsy as a result of metastatic disease.
Underlying CODs within the “other” category
included chronic alcoholism, hepatic encephalopathy,
diabetes mellitus, hypertension, systemic amyloidosis,
endocarditis, nephropathy, peripheral vascular dis-
ease, and ischemic bowel disease.
The distribution of immediate CODs is shown in
figure 1B. Pneumonia was themost common immediate
COD (31.2% or 59/189). Among individuals whose
immediate COD was pneumonia, the underlying
CODs were cerebrovascular disease (22.0% [13/59]),
other (17% [10/59]), noncerebral neoplasm (13.6%
[8/59]), congenital neurologic disorder (11.9%
[7/59]), cardiovascular disease (8.5% [5/59]), neurode-
generative disease (8.5% [5/59]), and epilepsy-related
(3.4% [2/59]). Among 9 (4.8%) individuals who died
of pneumonia, an underlying COD was not indicated
on the death certificate.
There were no evident differences in the proportions
of each underlying COD when stratified by timing of
death (#2 years vs .2 years after the index seizure)
(table e-1 on the Neurology® Web site at Neurology.
org). People age 60 years or younger at the time of the
index seizure as well as those age 60 years or younger at
the time of death were more likely to die of primary
cerebral neoplasm (15.1% vs 0.9%, p, 0.011, and 21.
3% vs 1.4%, p , 0.011, respectively) but were less
likely to die of cerebrovascular disease (2.7% vs 26.
7%, p , 0.011, and 4.3% vs 21.8%, p , 0.032,
respectively) (table e-1). People age 60 years or younger
at the time of death were also more likely to die of
external causes (12.8% vs 1.4%, p 5 0.03) or a con-
genital neurologic disorder (12.8% vs 1.4%, p5 0.03).
We found that in 22.8% (43/189) of deaths, the
underlying COD was directly related to the individu-
al’s epilepsy etiology. This proportion was as high as
57.5% during the first 2 years of follow-up, decreas-
ing to 6.0% after .15 years of follow-up (figure 2,
with further details in table e-2). Overall, among peo-
ple dying within 2 years of their index seizure, there
was a more than fourfold greater chance that the cause
of their epilepsy was directly related to their underly-
ing COD (percent ratio 4.28, 95% confidence inter-
val [CI] 2.63–6.97; p , 0.0001) as compared to
people who died more than 2 years after their index
seizure. The epilepsy etiologies of the 189 individuals
who died are listed in table e-3.
The results of our survival analyses examining for
predictors of mortality are presented in tables 2 and 3.
Male sex was found to be protective, with a roughly
30% decrease in the risk of death (adjusted hazard
ratios [HRs] 0.69 and 0.70). Early epilepsy remission
was also protective (adjusted HRs 0.61 and 0.66).
Of the comorbidities of epilepsy, ICD chapters 2
(neoplasms), 4 (endocrine, nutritional, and metabolic
diseases), 13 (diseases of the musculoskeletal system
and connective tissue), 17 (congenital malformations,
deformations, and chromosomal abnormalities), and
19/20 (injury, poisoning, and certain other conse-
quences of external causes/external causes of morbid-
ity and mortality) were significant predictors of
mortality (table 2). ICD chapter 13 was the only
chapter whose presence predicted a decreased risk of
mortality (adjusted HR 0.42 [95% CI 0.19–0.91]).
Table 1 Study participant characteristics
(n 5 558)
Characteristics Valuesa
Male sex 291 (52)
Epilepsy etiology
Remote symptomatic 132 (24)
Idiopathic/cryptogenic 426 (76)
Early epilepsy remissionb 183 (33)
All-cause mortality 190 (34)c
Age at index seizure, y
Entire cohort 24.4 (13.8–56.1)d
Alive 17.1 (9.6–27.4)
Dead 64.2 (50.8–75.1)
Age at last follow-up, y
Entire cohort 47.4 (36.8–70.9)
Alive 40.9 (33.3–51.1)
Dead 74.8 (59.1–83.1)
Duration of follow-up, y
Entire cohort 23.0 (14.9–24.2)
Alive 23.9 (23.0–24.7)
Dead 8.1 (2.3–15.2)
aVariables presented as n (%) or median (interquartile
range).
bDefined as no recurrent seizures more than 1 year after
the index event.
cOne death certificate was missing and so this individual
was excluded from the cause of death–related analyses.
d Thirty-eight percent of individuals (212/558) were youn-
ger than 18 years.
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Examining the constituents of selected ICD chap-
ters, primary cerebral and noncerebral neoplasms,
dementia, Parkinson disease, cerebrovascular disease,
traumatic brain injury, and substance abuse were sig-
nificant and independent predictors of mortality
(table 3).
DISCUSSION The NGPSE is one of the largest pro-
spective community-based cohorts with almost 25
years follow-up examining the risk and determinants
of mortality among people with epilepsy.2,4,30 Prior
analyses of the NGPSE have reported the overall
standardized mortality ratio (SMR) for all-cause
Figure 1 Proportionate mortality ratio for underlying (A) and immediate (B) cause of death
NOS 5 not otherwise specified.
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mortality, stratified by age, timing after the index
seizure, and epilepsy etiology, as well as SMRs for
selected CODs.1,24,25 In this article, we report 3
novel main findings. First, we describe the complete
distribution of CODs, distinguish between underlying
and immediate CODs, and demonstrate that the
majority of deaths (59%) were due to noncerebral
neoplasms (only 29% of which were related to the
epilepsy etiology), cardiovascular disease, and
cerebrovascular disease, while epilepsy-related causes
accounted for only 3% of deaths. Pneumonia was the
most important immediate COD, representing what is
likely a common terminus in a fatal sequence of events.
Second, we demonstrate that overall 23% of underlying
CODs were directly related to an individual’s epilepsy
etiology and that this was fourfold as likely to be the
case if death occurred within 2 years of the index
seizure. Third, we demonstrate that several somatic
and psychiatric comorbidities are predictive of
mortality. When examining specific conditions,
neoplasms (primary cerebral and noncerebral
neoplasm), several neurologic diseases (dementia,
Parkinson disease, cerebrovascular disease, and
traumatic brain injury), and substance abuse were
independently associated with increased mortality risk.
The majority of deaths in our cohort were due to
noncerebral neoplasms, cardiovascular disease, and
cerebrovascular disease, while relatively few were
epilepsy-related. It is difficult to compare PMRs
between populations but our findings are generally
comparable to others in high-income countries. A
previous meta-analysis reported that 4% of deaths
in low-risk groups of people with epilepsy are due
to SUDEP31 (generally considered to be the most
common cause of epilepsy-related death).32 Our find-
ings emphasize that comorbidities similar to those
responsible for mortality in the general population33
are also the most important mediators of premature
death in people with epilepsy. The increased risk of
mortality from these diseases may be related to the
postulated proneoplastic effect of certain antiepileptic
drugs1 or the increased risk of metabolic syndrome
with others.34 It may also be that epilepsy is a surro-
gate in some instances for severe neoplastic or ather-
osclerotic disease, where individuals with more severe
forms of these comorbidities are more likely to
develop epilepsy as well as die prematurely. In either
case, at the level of the general population, physician
counseling of people with epilepsy with regards to
neoplastic and atherosclerotic risk factors appears to
be as important as counseling individuals on the risk
of SUDEP or status epilepticus, if not more so.
Only one other study has investigated the relation-
ship between epilepsy etiology and COD, showing
that in the first year of follow-up, 72.2% (39/54) of
CODs among those with remote symptomatic epi-
lepsy were related to the underlying epilepsy etiol-
ogy.14 We now confirm these findings, doing so
with a much larger cohort than the previous investi-
gators. We additionally demonstrate that this rela-
tionship between underlying COD and epilepsy
etiology weakens over time, which may explain why
mortality rates similarly decrease over time.1
We report a number of comorbid conditions that
significantly and independently predict mortality in
the NGPSE. One recent study reported that a life-
time history of certain psychiatric disorders (includ-
ing substance abuse) predicted increased risk of
death from external causes (largely suicide and acci-
dental death).11 We now demonstrate that a lifetime
history of substance abuse is a significant predictor of
not only death due to external causes but all-cause
mortality.
Our findings show that male sex was associated
with a 30% decrease in mortality risk, after control-
ling for age, early epilepsy remission, and comorbid-
ities. This is somewhat surprising as male sex is
typically associated with a shorter life expectancy.35
This merits further study.
Our study has a number of strengths. The
NGPSE is a prospective community-based cohort
of people with both adult and childhood-onset epi-
lepsy, allowing for a complete spectrum of people,
and has an exceptionally long period of follow-up.
Our method of assessing whether an individual has
died or not probably captured all deaths. Finally, we
carefully defined underlying and immediate COD
for each participant (using the official death certificate
but generally without the benefit of an autopsy),
Figure 2 Relationship between epilepsy etiology and underlying cause of death
(COD)
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while following rules as described by the WHO,
which is an important distinction if one’s ultimate
goal is to interrupt the fatal sequence of events leading
to death.23
Our study has limitations. The NGPSE relied
upon GP reporting of psychiatric and somatic comor-
bidities, via a combination of pointed and open-
ended questions. These data were sampled on 12 oc-
casions, up to 2001, after which no further
comorbidity information could be collected. We
expect that misclassification of each participant’s
comorbidity status (including failure to report an ex-
isting comorbidity) was probably independent of
their eventual survival outcome. As a result, any bias
would have led to an underestimation rather than an
overestimation of the associated risk, and therefore
any significant findings are likely to be true. The
NGPSE also relied upon the history and records
Table 2 Predictors of mortality (n 5 558)
Predictor
Simple modelsa Fully adjusted modela,b
Hazard ratio (95% CI) p Value Hazard ratio (95% CI) p Value
Age at index seizure, y
<15 (n 5 161) Reference — Reference —
15 to <30 (n 5 152) 1.56 (0.67–3.66) 0.302 1.74 (0.74–4.10) 0.206
30 to <60 (n 5 123) 9.55 (4.70–19.39)c ,0.001c 10.48 (5.09–21.56)c ,0.001c
‡60 (n 5 122) 52.69 (26.46–104.92)c ,0.001c 67.98 (33.09–139.64)c ,0.001c
Male sex (n 5 291) 0.77 (0.58–1.03) 0.077 0.69 (0.51–0.92)c 0.013c
Early epilepsy remissiond (n 5 183) 0.73 (0.53–1.00)c 0.047c 0.61 (0.44–0.83)c 0.002c
ICD-10 chapterse
1: Certain infectious and parasitic diseases (n 5 11) 1.62 (0.22–11.88) 0.633
2: Neoplasms (n 5 55) 3.05 (1.67–5.57)c ,0.001c 2.72 (1.47–5.04)c 0.001c
3: Diseases of the blood and blood-forming organs and certain
disorders involving the immune mechanism (n 5 15)
1.36 (0.60–3.11) 0.461
4: Endocrine, nutritional, and metabolic diseases (n 5 41) 3.10 (1.54–6.21)c 0.001c 3.36 (1.65–6.82)c 0.001c
5: Mental and behavioral disorders (n 5 135) 1.19 (0.77–1.83) 0.429
6: Diseases of the nervous system (n 5 83) 1.29 (0.68–2.46) 0.437
7: Diseases of the eye and adnexa (n 5 12) 0.47 (0.11–1.90) 0.286
8: Diseases of the ear and mastoid process (n 5 9) NAf —
9: Diseases of the circulatory system (n 5 119) 1.09 (0.68–1.75) 0.710
10: Diseases of the respiratory system (n 5 54) 1.27 (0.59–2.73) 0.539
11: Diseases of the digestive system (n 5 37) 1.49 (0.82–2.71) 0.188
12: Diseases of the skin and subcutaneous tissue (n 5 26) 1.10 (0.27–4.48) 0.893
13: Diseases of the musculoskeletal system and connective
tissue (n 5 32)
0.46 (0.21–0.99)c 0.048c 0.41 (0.19–0.88)c 0.022c
14: Diseases of the genitourinary system (n 5 18) 1.09 (0.40–2.95) 0.872
15: Pregnancy, childbirth, and the puerperium (n 5 7) NAf —
16: Certain conditions originating in the perinatal period (n 5 10) 3.35 (0.78–14.4) 0.105
17: Congenital malformations, deformations, and chromosomal
abnormalities (n 5 13)
4.84 (1.92–12.18)c 0.001c 5.20 (2.06–13.16)c ,0.001c
18: Symptoms, signs, and abnormal clinical and laboratory findings,
not elsewhere classified (n 5 13)
1.84 (0.68–4.97) 0.229
19/20: Injury, poisoning, and certain other consequences of external
causes/external causes of morbidity and mortality (n 5 45)
2.62 (1.21–5.69)c 0.015c 2.67 (1.21–5.92)c 0.015c
Abbreviation: CI 5 confidence interval.
a All models included age at index seizure and sex as covariates.
b This model also included early epilepsy remission as well as any ICD-10 chapter that was found to have a p , 0.10 in the simple models.
c Significant.
dDefined as no recurrent seizures more than 1 year after the index event.
e ICD-10, classifying human disease into 20 broad categories.
f Not available; could not be calculated due to collinearity.
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Table 3 Expanded ICD-10 chapters as predictors of mortality (n 5 558)
Predictor
Simple modelsa Fully adjusted modela,b
Hazard ratio (95% CI) p Value Hazard ratio (95% CI) p Value
Age at index seizure, y
<15 (n 5 161) Reference — Reference —
15 to <30 (n 5 152) 1.56 (0.67–3.66) 0.302 1.95 (0.81–4.65) 0.134
30 to <60 (n 5 123) 9.55 (4.70–19.39)c 0.001c 11.16 (5.31–23.45)c ,0.001c
‡60 (n 5 122) 52.69 (26.46–104.92)c ,0.001c 59.23 (27.89–125.78)c ,0.001c
Male sex (n 5 291) 0.77 (0.58–1.03) 0.077 0.70 (0.52–0.95)c 0.021c
Early epilepsy remission (n 5 183) 0.73 (0.53–1.00)c 0.047c 0.66 (0.48–0.93)c 0.016c
ICD chapter 2d
Primary cerebral neoplasm (n 5 22) 4.36 (2.65–7.17)c ,0.001c 5.02 (2.99–8.43)c ,0.001c
Noncerebral neoplasm (n 5 34) 3.08 (1.68–5.65)c ,0.001c 4.22 (2.25–7.89)c ,0.001c
ICD chapter 4
Diabetes mellitus, obesity, or hypercholesterolemia (n 5 30) 2.77 (1.21–6.39)c 0.016c 1.17 (0.41–3.33) 0.762
Other (n 5 14) 2.77 (1.11–6.95)c 0.029c 2.12 (0.68–6.58) 0.194
ICD chapter 5
Depression (n 5 42) 0.55 (0.26–1.19) 0.131
Anxiety (n 5 11) 1.09 (0.26–4.46) 0.909
Substance abuse (n 5 27) 3.63 (1.33–9.88)c 0.012c 5.42 (1.92–15.26)c 0.001c
Dementia (n 5 41) 2.30 (1.32–4.00)c 0.003c 2.75 (1.51–5.01)c 0.001c
Learning disability (n 5 22) 2.58 (1.11–6.03)c 0.028c 2.10 (0.86–5.12) 0.104
Other (n 5 20) 1.65 (0.21–12.88) 0.630
ICD chapter 6
Migraine (n 5 30) 1.77 (0.76–4.10) 0.186
Parkinson disease (n 5 8) 3.53 (1.40–8.88)c 0.007c 5.09 (1.99–13.02)c 0.001c
Focal neurologic deficit (n 5 11) 1.05 (0.14–7.57) 0.964
Other (n 5 34) 0.95 (0.35–2.61) 0.926
ICD chapter 9
Cerebrovascular disease (n 5 53) 2.93 (1.47–5.83)c 0.002c 3.96 (1.96–8.04)c ,0.001c
Cardiac disease (n 5 45) 1.13 (0.65–1.96) 0.674
Hypertension (n 5 37) 1.10 (0.44–2.74) 0.843
Other (n 5 20) 1.46 (0.68–3.14) 0.9184
ICD chapter 13
Inflammatory musculoskeletal disease (n 5 14) 0.23 (0.03–1.62) 0.139
Degenerative musculoskeletal disease (n 5 13) 0.55 (0.22–1.35) 0.190
Other (n 5 5) 0.94 (0.13–6.80) 0.951
ICD chapter 17
Congenital malformations, deformations, and chromosomal
abnormalities (n 5 13)
4.84 (1.92–12.18)c 0.001c 4.89 (1.85–12.87)c 0.001c
ICD chapter 19/20
Traumatic brain injury (n 5 32) 5.67 (1.34–23.98)c 0.018c 9.80 (2.30–41.68)c 0.002c
Any fracture without brain injury (n 5 9) 2.52 (0.92–6.90) 0.073 2.06 (0.71–5.95) 0.182
Other (n 5 4) 1.27 (0.17–9.22) 0.816
Abbreviation: CI 5 confidence interval.
a All models included age at index seizures and sex as covariates.
b This model also included early epilepsy remission as well as any comorbidity that was found to have a p , 0.10 in the simple models.
c Significant.
d The number with each comorbidity will not necessarily equate with those numbers presented in table 2, given that a single individual may have more than
one comorbidity within each chapter.
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provided by GPs in the 1980s to establish the etiology
of each person’s epilepsy without the benefit of mod-
ern imaging techniques. This inevitably means that
some individuals labeled as having cryptogenic epi-
lepsy would have a declared etiology if the study were
repeated today. Practically speaking, however, the
repetition of such a study seems remote given the
current research environment and requirements for
individual consent, at least in the United Kingdom.
This study presents a number of important find-
ings related to improving our understanding of the
determinants of premature mortality in epilepsy.
These findings represent important opportunities
for future research and potential avenues for preven-
tative strategies and initiatives.
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